A retrospective study assessing the outcomes of induction chemotherapy with 7+3-Ida and midostaurin in elderly patients at least 60 years of age with FLT3 mutated, treatment-naïve Acute myelogenous leukemia
Latest Information Update: 17 Jul 2020
At a glance
- Drugs Idarubicin (Primary) ; Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association